With highly experienced diabetes and endocrinology specialists at Columbia and Weill Cornell Medicine, our programs are recognized for excellence in achieving optimal outcomes for challenging metabolic conditions and chronic diseases by providing multidisciplinary care to all patients. Our experts conduct research on developing innovative treatments and compassionately address the physical and emotional toll these prolonged diseases can have on patients and their families.
Featured Updates
Results from a new multi-center study, led by oncologists at NewYork-Presbyterian and Weill Cornell Medicine, has described for the first time a key biomarker – absolute lymphocyte count (ALC) – that has the potential to predict therapeutic response to chimeric antigen receptor (CAR) T-cell immunotherapy for patients with relapsed/refractory multiple myeloma. While this FDA-approved treatment is widely used, until now there has not been a way to predict whether B-cell maturation antigen (BCMA) CAR T-cell therapy would elicit a good response.
The Latest
Pediatric Neurology & Neurosurgery
Crossing Specialty Lines for Rare Genetic Neurocutaneous Conditions
